On Invalid Date, Phaxiam Therapeutics Sa (NASDAQ: PHXM) reported Q2 2023 earnings per share (EPS) of N/A, up N/A year over year. Total Phaxiam Therapeutics Sa earnings for the quarter were N/A. In the same quarter last year, Phaxiam Therapeutics Sa's earnings per share (EPS) was N/A.
As of Q4 2023, Phaxiam Therapeutics Sa's earnings has grown year over year. Phaxiam Therapeutics Sa's earnings in the past year totalled -$12.13 million.
What is PHXM's earnings date?
Phaxiam Therapeutics Sa's earnings date is Invalid Date. Add PHXM to your watchlist to be reminded of PHXM's next earnings announcement.
What was PHXM's revenue last quarter?
On Invalid Date, Phaxiam Therapeutics Sa (NASDAQ: PHXM) reported Q2 2023 revenue of N/A up N/A year over year. In the same quarter last year, Phaxiam Therapeutics Sa's revenue was N/A.
What was PHXM's revenue growth in the past year?
As of Q4 2023, Phaxiam Therapeutics Sa's revenue has grown -77.09% year over year. This is 176.59 percentage points lower than the US Biotechnology industry revenue growth rate of 99.5%. Phaxiam Therapeutics Sa's revenue in the past year totalled $6.35 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.